Spots Global Cancer Trial Database for stage iv squamous cell carcinoma of the oropharynx
Every month we try and update this database with for stage iv squamous cell carcinoma of the oropharynx cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Irinotecan and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | NCT00639769 | Head and Neck C... | cisplatin irinotecan hydr... | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Cisplatin With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer | NCT00003809 | Head and Neck C... | cetuximab cisplatin | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Gefitinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III or Stage IV Head and Neck Cancer | NCT00033449 | Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... | gefitinib radiation thera... cisplatin laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Liposomal Lurtotecan Plus Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors | NCT00006036 | Head and Neck C... Lung Cancer Ovarian Cancer Unspecified Adu... | cisplatin lurtotecan lipo... | 18 Years - 120 Years | Canadian Cancer Trials Group | |
| Docetaxel in Treating Patients With Solid Tumors and Abnormal Liver Function | NCT00002901 | Breast Cancer Head and Neck C... Lung Cancer Ovarian Cancer Unspecified Adu... | docetaxel | 18 Years - | City of Hope Medical Center | |
| Irinotecan and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer | NCT00040807 | Head and Neck C... | docetaxel irinotecan hydr... | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| NGR-TNF in Treating Patients With Advanced Solid Tumors | NCT00098943 | Colorectal Canc... Head and Neck C... Kidney Cancer Unspecified Adu... | CNGRC peptide-T... | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Radiation Therapy With or Without Epoetin Alfa in Treating Anemic Patients With Head and Neck Cancer | NCT00004917 | Anemia Head and Neck C... | epoetin alfa cisplatin radiation thera... | 18 Years - | Radiation Therapy Oncology Group | |
| Bevacizumab, Docetaxel, and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer | NCT00281840 | Head and Neck C... | bevacizumab docetaxel conventional su... radiation thera... | 18 Years - | Case Comprehensive Cancer Center | |
| Adjuvant Cetuximab and Chemoradiotherapy Using Either Cisplatin or Docetaxel in Treating Patients With Resected Stage III or Stage IV Squamous Cell Carcinoma or Lymphoepithelioma of the Head and Neck | NCT00084318 | Head and Neck C... | cetuximab cisplatin docetaxel radiation thera... | 18 Years - | Radiation Therapy Oncology Group | |
| PEG-interferon Alfa-2b in Treating Patients With Stage II, Stage III, or Stage IV Head and Neck Cancer That Can Be Removed By Surgery | NCT00276523 | Head and Neck C... | PEG-interferon ... Conventional su... Neoadjuvant the... | 18 Years - | M.D. Anderson Cancer Center | |
| Protein Expression in Tumor Tissue Samples From Patients With Cancer of the Oropharynx | NCT00899340 | Head and Neck C... | gene expression... microarray anal... protein express... immunohistochem... laboratory biom... | - | Vanderbilt-Ingram Cancer Center | |
| Cetuximab Plus Cisplatin in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck That Has Not Responded to Cisplatin Chemotherapy | NCT00004865 | Head and Neck C... | cetuximab cisplatin fluorouracil paclitaxel | 18 Years - | National Cancer Institute (NCI) | |
| Cetuximab, Carboplatin, and Paclitaxel Followed by Radiation Therapy, With or Without Cisplatin, in Treating Patients With Metastatic Head and Neck Cancer | NCT00301028 | Head and Neck C... | Cetuximab Carboplatin Paclitaxel Conventional Su... Radiation Thera... | 16 Years - | M.D. Anderson Cancer Center | |
| Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Head and Neck Cancer | NCT00002654 | Head and Neck C... | chemotherapy cisplatin low-LET cobalt-... low-LET electro... low-LET photon ... | 20 Years - 75 Years | Swiss Group for Clinical Cancer Research | |
| Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer | NCT00003888 | Head and Neck C... | cisplatin docetaxel fluorouracil radiation thera... | 18 Years - 70 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| Biomarkers of Response in Blood and Tumor Tissue Samples From Patients With Unresectable Stage IV Squamous Cell Cancer of the Head and Neck Previously Treated With Cetuximab, Cisplatin, and Radiation Therapy | NCT01194635 | Head and Neck C... | fluorescence in... gene expression... polymerase chai... protein analysi... protein express... enzyme-linked i... immunohistochem... laboratory biom... | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer | NCT00006107 | Head and Neck C... | Taxotere Surgery radiation thera... | 18 Years - | Dana-Farber Cancer Institute | |
| Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer | NCT00023959 | Metastatic Squa... Recurrent Adeno... Recurrent Basal... Recurrent Esthe... Recurrent Inver... Recurrent Lymph... Recurrent Lymph... Recurrent Metas... Recurrent Midli... Recurrent Mucoe... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Stage III Adeno... Stage III Basal... Stage III Esthe... Stage III Inver... Stage III Lymph... Stage III Lymph... Stage III Midli... Stage III Mucoe... Stage III Saliv... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Verru... Stage III Verru... Stage IV Adenoi... Stage IV Basal ... Stage IV Esthes... Stage IV Invert... Stage IV Lympho... Stage IV Lympho... Stage IV Midlin... Stage IV Mucoep... Stage IV Saliva... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Verruc... Stage IV Verruc... Untreated Metas... | hydroxyurea fluorouracil bevacizumab radiation thera... filgrastim laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Flavopiridol in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | NCT00020189 | Head and Neck C... Thromboembolism | acetylsalicylic... alvocidib clopidogrel bis... | 18 Years - | National Cancer Institute (NCI) | |
| 3'-Deoxy-3'-[18F] Fluorothymidine and Fludeoxyglucose F 18 PET Scans in Evaluating Response to Cetuximab, Cisplatin, and Radiation Therapy in Patients With Advanced Cancer of the Oropharynx, Larynx, or Hypopharynx | NCT00757549 | Head and Neck C... | cetuximab cisplatin TdT-mediated dU... 3'-deoxy-3'-[18... immunohistochem... laboratory biom... fludeoxyglucose... radiation thera... | 18 Years - 120 Years | Mayo Clinic | |
| Germline Mutations in Patients With Head and Neck Cancer and a Family History of Cancer | NCT00482872 | Head and Neck C... | gene expression... mutation analys... polymerase chai... polymorphism an... flow cytometry laboratory biom... | 18 Years - 120 Years | Vanderbilt University Medical Center | |
| Salivary Gland Surgery Before Radiation Therapy in Preventing Radiation-Caused Xerostomia in Patients With Head and Neck Cancer | NCT00068237 | Head and Neck C... Radiation Toxic... Xerostomia | salivary gland ... Post-operative ... | 18 Years - | Radiation Therapy Oncology Group | |
| Study of Blood and Tissue Samples From Patients With Larynx Cancer, Pharynx Cancer, or Oral Cavity Cancer | NCT00963326 | Head and Neck C... | laboratory biom... | 15 Years - | National Cancer Institute (NCI) | |
| Bortezomib and Docetaxel in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | NCT00425750 | Head and Neck C... | bortezomib docetaxel laboratory biom... pharmacological... | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer | NCT00720083 | Head and Neck C... | cisplatin vandetanib radiation thera... | 18 Years - | Radiation Therapy Oncology Group | |
| Carboplatin, Capecitabine, and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer | NCT00114153 | Head and Neck C... | capecitabine carboplatin conventional su... radiation thera... | 18 Years - | National Cancer Institute (NCI) | |
| Oxaliplatin in Treating Patients With Advanced Head and Neck Cancer | NCT00005035 | Head and Neck C... | oxaliplatin | 18 Years - | National Cancer Institute (NCI) | |
| Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Larynx or Oropharynx Cancer | NCT00014118 | Head and Neck C... | carboplatin paclitaxel conventional su... radiation thera... | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) | NCT00031681 | Advanced Adult ... Carcinoma of th... Estrogen Recept... Extensive Stage... Gastrointestina... HER2-negative B... Metastatic Gast... Ovarian Sarcoma Ovarian Stromal... Progesterone Re... Recurrent Adeno... Recurrent Adult... Recurrent Anal ... Recurrent Basal... Recurrent Borde... Recurrent Breas... Recurrent Cervi... Recurrent Colon... Recurrent Endom... Recurrent Esoph... Recurrent Esthe... Recurrent Extra... Recurrent Gallb... Recurrent Gastr... Recurrent Gastr... Recurrent Inver... Recurrent Lymph... Recurrent Lymph... Recurrent Metas... Recurrent Midli... Recurrent Mucoe... Recurrent Non-s... Recurrent Ovari... Recurrent Ovari... Recurrent Pancr... Recurrent Prost... Recurrent Recta... Recurrent Saliv... Recurrent Small... Recurrent Small... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Small Intestine... Small Intestine... Small Intestine... Stage IV Adenoi... Stage IV Anal C... Stage IV Basal ... Stage IV Border... Stage IV Breast... Stage IV Colon ... Stage IV Endome... Stage IV Esopha... Stage IV Esthes... Stage IV Gastri... Stage IV Invert... Stage IV Lympho... Stage IV Lympho... Stage IV Midlin... Stage IV Mucoep... Stage IV Non-sm... Stage IV Ovaria... Stage IV Ovaria... Stage IV Pancre... Stage IV Prosta... Stage IV Rectal... Stage IV Saliva... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Verruc... Stage IV Verruc... Stage IVA Cervi... Stage IVB Cervi... Triple-negative... Unresectable Ex... Unresectable Ga... Unspecified Adu... Untreated Metas... | 7-hydroxystauro... irinotecan hydr... diagnostic labo... | 18 Years - | National Cancer Institute (NCI) | |
| DNA Analysis of Tissue Samples From Patients With Head and Neck Cancer | NCT00898664 | Head and Neck C... | cytogenetic ana... gene expression... mutation analys... polymerase chai... immunohistochem... laboratory biom... | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Combination Chemotherapy and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer | NCT00352118 | Head and Neck C... | filgrastim pegfilgrastim cisplatin docetaxel fluorouracil conventional su... radiation thera... | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Docetaxel in Treating Patients With Solid Tumors and Abnormal Liver Function | NCT00002901 | Breast Cancer Head and Neck C... Lung Cancer Ovarian Cancer Unspecified Adu... | docetaxel | 18 Years - | City of Hope Medical Center | |
| Protein Expression in Tumor Tissue Samples From Patients With Cancer of the Oropharynx | NCT00899340 | Head and Neck C... | gene expression... microarray anal... protein express... immunohistochem... laboratory biom... | - | Vanderbilt-Ingram Cancer Center | |
| Boronophenylalanine-Fructose Complex (BPA-F) and/or Sodium Borocaptate (BSH) Followed By Surgery in Treating Patients With Thyroid Cancer, Head and Neck Cancer, or Liver Metastases | NCT00062348 | Colorectal Canc... Head and Neck C... Metastatic Canc... | boronophenylala... sodium borocapt... conventional su... | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Docetaxel in Treating Patients With Solid Tumors and Abnormal Liver Function | NCT00002901 | Breast Cancer Head and Neck C... Lung Cancer Ovarian Cancer Unspecified Adu... | docetaxel | 18 Years - | City of Hope Medical Center | |
| Study of Blood and Tissue Samples From Patients With Larynx Cancer, Pharynx Cancer, or Oral Cavity Cancer | NCT00963326 | Head and Neck C... | laboratory biom... | 15 Years - | National Cancer Institute (NCI) | |
| Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III or Stage IV Cancer of the Oropharynx, Hypopharynx, or Larynx | NCT00004227 | Head and Neck C... | cetuximab conventional su... radiation thera... | 18 Years - | University of Alabama at Birmingham | |
| Radiation Therapy Plus Porfiromycin in Treating Patients With Stage III or Stage IV Head and Neck Cancer | NCT00003328 | Head and Neck C... | porfiromycin radiation thera... | 18 Years - | National Cancer Institute (NCI) | |
| SWOG-9451, Combination Chemo & RT For Patients With Stage III/Stage IV Cancer of the Hypopharynx or Tongue | NCT00002735 | Head and Neck C... | Induction chemo... cisplatin fluorouracil low-LET cobalt-... | 18 Years - 120 Years | SWOG Cancer Research Network | |
| Bortezomib, Cetuximab, and Radiation Therapy With or Without Cisplatin in Treating Patients With Stage IV Head and Neck Cancer | NCT00629226 | Head and Neck C... | cetuximab bortezomib cisplatin intensity-modul... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| EF5 Compared With Other Methods of Detecting Oxygen Levels in Tumor Cells of Patients With Head and Neck Cancer | NCT00049140 | Head and Neck C... | EF5 bioluminescence flow cytometry immunohistochem... biopsy | 18 Years - | Duke University | |
| Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery | NCT00041171 | Adult Solid Tum... Breast Cancer Head and Neck C... Kidney and Urin... Male Reproducti... Thorax and Resp... | Hypericum perfo... docetaxel placebo | 18 Years - 120 Years | Alliance for Clinical Trials in Oncology | |
| Cisplatin and Radiation Therapy With or Without Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Head and Neck Cancer | NCT00410826 | Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... | erlotinib hydro... cisplatin 3-dimensional c... intensity-modul... quality-of-life... | 18 Years - | University of Washington | |
| AP5346 or Oxaliplatin in Treating Patients With Metastatic and/or Unresectable Recurrent Head and Neck Cancer | NCT00415298 | Head and Neck C... | DACH polymer pl... oxaliplatin gene expression... immunohistochem... pharmacological... biopsy | 18 Years - | National Cancer Institute (NCI) | |
| Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors | NCT00089362 | Male Breast Can... Recurrent Adeno... Recurrent Basal... Recurrent Breas... Recurrent Colon... Recurrent Esthe... Recurrent Gastr... Recurrent Inver... Recurrent Lymph... Recurrent Lymph... Recurrent Melan... Recurrent Metas... Recurrent Midli... Recurrent Mucoe... Recurrent Ovari... Recurrent Prost... Recurrent Renal... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Stage III Adeno... Stage III Basal... Stage III Colon... Stage III Esthe... Stage III Gastr... Stage III Inver... Stage III Lymph... Stage III Lymph... Stage III Melan... Stage III Midli... Stage III Mucoe... Stage III Ovari... Stage III Renal... Stage III Saliv... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Verru... Stage III Verru... Stage IIIB Brea... Stage IIIC Brea... Stage IV Adenoi... Stage IV Basal ... Stage IV Breast... Stage IV Colon ... Stage IV Esthes... Stage IV Gastri... Stage IV Invert... Stage IV Lympho... Stage IV Lympho... Stage IV Melano... Stage IV Midlin... Stage IV Mucoep... Stage IV Ovaria... Stage IV Prosta... Stage IV Renal ... Stage IV Saliva... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Verruc... Stage IV Verruc... Unspecified Adu... Untreated Metas... | alvespimycin hy... laboratory biom... pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer | NCT00897793 | Breast Cancer Colorectal Canc... Head and Neck C... Lung Cancer Prostate Cancer | venipuncture radiation thera... | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Erlotinib in Treating Patients With Metastatic and/or Recurrent Head and Neck Cancer | NCT00281866 | Head and Neck C... | erlotinib hydro... | 18 Years - 120 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Docetaxel, Cisplatin, and Fluorouracil Followed By Cetuximab and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer | NCT00721513 | Head and Neck C... | cetuximab cisplatin docetaxel fluorouracil computed tomogr... positron emissi... quality-of-life... 3-dimensional c... intensity-modul... | 18 Years - 120 Years | Wake Forest University Health Sciences | |
| Nab-Paclitaxel, Cisplatin, and Cetuximab With Concurrent Radiation Therapy for Locally Advanced Head and Neck Cancer | NCT00851877 | Head and Neck C... | Cetuximab Cisplatin Nab-Paclitaxel intensity-modul... | 18 Years - 120 Years | University of Texas Southwestern Medical Center | |
| EF5 Compared With Other Methods of Detecting Oxygen Levels in Tumor Cells of Patients With Head and Neck Cancer | NCT00049140 | Head and Neck C... | EF5 bioluminescence flow cytometry immunohistochem... biopsy | 18 Years - | Duke University | |
| Docetaxel in Treating Patients With Solid Tumors | NCT00003565 | Bladder Cancer Breast Cancer Head and Neck C... Lung Cancer Unspecified Adu... | docetaxel | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Gene and Protein Expression Patterns in Predicting Response to Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer | NCT00898742 | Head and Neck C... | DNA and tissue ... reverse transcr... mass spectromet... | - | Vanderbilt-Ingram Cancer Center | |
| Bortezomib and Docetaxel in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | NCT00425750 | Head and Neck C... | bortezomib docetaxel laboratory biom... pharmacological... | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Amifostine Plus Chemotherapy and Radiation Therapy in Treating Patients With Advanced, Unresectable Head and Neck Cancer | NCT00003251 | Drug/Agent Toxi... Head and Neck C... Radiation Toxic... | amifostine trih... cisplatin paclitaxel radiation thera... | 18 Years - | National Cancer Institute (NCI) | |
| Adjuvant Erlotinib After Completing Chemoradiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck | NCT00079053 | Head and Neck C... | erlotinib hydro... adjuvant therap... | 18 Years - 120 Years | Canadian Cancer Trials Group | |
| S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer | NCT00337129 | Head and Neck C... | eribulin mesyla... | 18 Years - | National Cancer Institute (NCI) | |
| S0217, Adjuvant Cisplatin and Docetaxel After Complete Resection Stage III or IV Head and Neck Cancer | NCT00084435 | Head and Neck C... | cisplatin docetaxel radiation thera... | 18 Years - | SWOG Cancer Research Network | |
| Radiation Therapy in Treating Patients With Head and Neck Cancer | NCT00021125 | Head and Neck C... Non-melanomatou... | adjuvant therap... radiation thera... | - | National Cancer Institute (NCI) | |
| Biomarkers in Predicting Response to Treatment in Patients With Newly Diagnosed Stage III or Stage IV Head and Neck Cancer Treated With Carboplatin, Paclitaxel, and Radiation Therapy | NCT00898430 | Head and Neck C... | DNA Microarray ... MALDI-TOF mass ... DNA microarray ... | - | Vanderbilt-Ingram Cancer Center | |
| Blood Proteins in Predicting Treatment Benefit in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer | NCT00896675 | Head and Neck C... | proteomic profi... proteomic profi... | - | Vanderbilt-Ingram Cancer Center | |
| Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck | NCT00720304 | Head and Neck C... | docetaxel erlotinib hydro... fluorescence in... polymerase chai... immunoenzyme te... immunohistochem... laboratory biom... pharmacological... therapeutic con... intensity-modul... radiation thera... | 18 Years - | Case Comprehensive Cancer Center | |
| Microsphere-Delivered Cytokines in Increasing Tumor Response in Lymphocytes From Patients With Head and Neck Cancer | NCT00899821 | Head and Neck C... | aldesleukin recombinant int... sargramostim immunologic tec... biopsy | 20 Years - 80 Years | NYU Langone Health | |
| Irinotecan and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | NCT00639769 | Head and Neck C... | cisplatin irinotecan hydr... | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Induction Chemotherapy Followed By Cetuximab and Radiation in HPV-Associated Resectable Stage III/IV Oropharynx Cancer | NCT01084083 | Head and Neck C... Precancerous Co... | cetuximab intensity-modul... Paclitaxel Cisplatin | 18 Years - | Eastern Cooperative Oncology Group | |
| Interleukin-2 Gene or Methotrexate in Treating Patients With Recurrent or Refractory Stage III or Stage IV Head and Neck Cancer | NCT00006033 | Head and Neck C... | gene therapy interleukin-2 g... methotrexate | 18 Years - | National Cancer Institute (NCI) | |
| Radiation Therapy, Combination Chemotherapy, and Amifostine in Treating Patients With Head and Neck Cancer | NCT00003582 | Carcinoma of Un... Head and Neck C... | amifostine trih... cisplatin fluorouracil paclitaxel quality-of-life... radiation thera... | 18 Years - 120 Years | University of Miami | |
| Oral Mucositis in Patients Receiving Radiation Therapy for Cancer of the Mouth, Pharynx, or Larynx | NCT00004234 | Head and Neck C... Oral Complicati... | management of t... radiation thera... | 16 Years - 120 Years | Canadian Cancer Trials Group | |
| Everolimus and Docetaxel in Treating Patients With Recurrent, Locally Advanced, or Metastatic Head and Neck Cancer | NCT01313390 | Head and Neck C... | docetaxel everolimus laboratory biom... pharmacological... | 18 Years - | University College, London | |
| Oral Mucositis in Patients Receiving Radiation Therapy for Cancer of the Mouth, Pharynx, or Larynx | NCT00004234 | Head and Neck C... Oral Complicati... | management of t... radiation thera... | 16 Years - 120 Years | Canadian Cancer Trials Group | |
| Cetuximab and Combination Chemotherapy in Patients With Stage III-IV Resectable Oropharynx Cancer | NCT00665392 | Head and Neck C... | cisplatin docetaxel fluorouracil Cetuximab | 18 Years - 75 Years | GERCOR - Multidisciplinary Oncology Cooperative Group | |
| Bevacizumab, Docetaxel, and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer | NCT00281840 | Head and Neck C... | bevacizumab docetaxel conventional su... radiation thera... | 18 Years - | Case Comprehensive Cancer Center | |
| Gefitinib, Paclitaxel, and Radiation Therapy in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck | NCT00083057 | Head and Neck C... | gefitinib paclitaxel radiation thera... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| S0011, Gene Therapy & Surgery Followed by Chemo & RT in Newly Diagnosed Cancer of the Mouth or Throat | NCT00017173 | Head and Neck C... | Ad5CMV-p53 gene cisplatin conventional su... radiation thera... | 18 Years - | SWOG Cancer Research Network | |
| Parotid-Sparing Intensity-Modulated Radiation Therapy Compared With Conventional Radiation Therapy in Treating Patients With Oropharyngeal or Hypopharyngeal Cancer Who Are at High Risk of Radiation-Induced Xerostomia | NCT00081029 | Head and Neck C... Radiation Toxic... Xerostomia | management of t... radiation thera... | - | National Cancer Institute (NCI) | |
| Germline Mutations in Patients With Head and Neck Cancer and a Family History of Cancer | NCT00482872 | Head and Neck C... | gene expression... mutation analys... polymerase chai... polymorphism an... flow cytometry laboratory biom... | 18 Years - 120 Years | Vanderbilt University Medical Center | |
| Study of Nutrition Regimens in Treating Patients With Cancer of the Upper Aerodigestive Tract | NCT00765440 | Head and Neck C... Infection Malnutrition | therapeutic nut... placebo | 18 Years - 75 Years | Centre Antoine Lacassagne | |
| Liposomal Lurtotecan Plus Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors | NCT00006036 | Head and Neck C... Lung Cancer Ovarian Cancer Unspecified Adu... | cisplatin lurtotecan lipo... | 18 Years - 120 Years | Canadian Cancer Trials Group | |
| Docetaxel, Cisplatin, and Fluorouracil Followed By Cetuximab and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer | NCT00721513 | Head and Neck C... | cetuximab cisplatin docetaxel fluorouracil computed tomogr... positron emissi... quality-of-life... 3-dimensional c... intensity-modul... | 18 Years - 120 Years | Wake Forest University Health Sciences | |
| Radiation Therapy With or Without Chemotherapy in Treating Patients With Head and Neck Cancer That Has Been Removed During Surgery | NCT00002670 | Head and Neck C... | chemotherapy cisplatin low-LET cobalt-... low-LET electro... low-LET photon ... | 18 Years - | Radiation Therapy Oncology Group |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
